ChAd63 PvDBP + MVA PvDBP

ChAd63 PvDBP + MVA PvDBP is a heterologous prime-boost malaria vaccine candidate targeting *Plasmodium vivax*. The regimen uses two recombinant viral vectors to deliver the gene encoding region II of the Duffy-binding protein (PvDBPII) from *Plasmodium vivax*: chimpanzee adenovirus 63 (ChAd63) as the priming vector and modified vaccinia virus Ankara (MVA) as the booster. Both vectors are genetically engineered to express the same malaria antigen. The vaccines are administered sequentially—ChAd63 PvDBP first, followed by MVA PvDBP approximately 8 weeks later. The goal is to induce both antibody and cellular immune responses against the blood-stage of *Plasmodium vivax* by generating immunity to a key protein required for parasite invasion of human red blood cells. Developed primarily for prevention of vivax malaria in healthy adults, this combination has been evaluated in Phase I/IIa clinical trials but did not demonstrate sufficient efficacy in reducing parasite growth or delaying symptoms compared with controls[1][3][4][5][6]. Both components were well tolerated with mainly mild and short-lived side effects.

Other names

ChAd63/MVA PvDBPVV-PvDBPII